Pulse.

a daily field guide to health research that matters

◆ Console

‹ Thu · 12 Nov 2026
Standard addition

Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.

A medication helped preserve muscle mass in people taking weight-loss drugs, suggesting a way to maintain strength during intentional weight reduction.

This randomized double-blind placebo-controlled phase 2 trial examined Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial. This study establishes proof of concept for GDF8 inhibition by trevogrumab alone as a generally well tolerated strategy to preserve lean mass during GLP-1 receptor agonist-induced weight loss.

What the study was

Study design
Randomized double-blind placebo-controlled phase 2 trial
Sample size
605
Category
Treatment Innovation
Maturity
Validated
Journal
Lancet (London, England)

Why it surfaced

Retained after review of PubMed metadata and abstract because its randomized double-blind placebo-controlled phase 2 trial directly informs cardiovascular-metabolic; scoring was capped conservatively for design and evidence maturity.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.